chimeric antigen receptor

One of the new therapies for mesothelioma is called antigen receptor T-cell therapy. It gives promise to malignant mesothelioma patients. This unique therapy has recently shown that it works in phase I clinical trials. A new report from French scientists details the current state of this therapy. This therapy has only been tested in a highly selected patient population. And it requires highly complex engineering. Yet, the treatment therapy shows promise. Adapting CAR T-Cell Therapy to Mesothelioma Malignant pleural and peritoneal mesothelioma are rare and aggressive cancers. They have had limited treatment options with moderate survival benefits. And all treatments have an impaired quality of life for a very long period. A chemotherapy drug combination known as cisplatin–pemetrexed has been…